Regulatory News In Brief

FDA issues final rule on good manufacturing practices for combination products. Rule withdrawn on scientific misconduct policy. More regulatory news.

FDA will issue a long-awaited final rule Jan. 22 on current good manufacturing practice (CGMP) requirements for combination products. The rule clarifies which manufacturing quality requirements apply when drugs, devices and biological products are combined to create combination products. The rule finalizes a September 2009 proposed rule, which itself took four years to develop. (See Also see "Proposed Rule Defines Good Manufacturing Practices For Combo Products" - Medtech Insight, 28 September, 2009..) The regulation also lays out a streamlined approach for firms that make single-entity or co-packaged combo products at the same facility. These firms can adopt one operating system as the baseline, and then add additional procedures as needed. FDA notes that the final rule is “largely identical” to the proposed rule. The agency made minor adjustments based on the 25 comments it received on the proposal.

FDA will also issue a draft guidance document Jan. 22 on submissions for post-approval modifications to a combination...

More from Regulation

More from Policy & Regulation

Medicare Tricuspid Regurgitation Coverage Decision Big Win For Abbott

 

Medicare beneficiaries with tricuspid regurgitation will now have access to an innovative treatment from Abbott that offers a minimally invasive alternative to open-heart surgery.

Warning Letters – June 2025

The US FDA posted eight device-related warning letters in June, touching on industry sectors from urinalysis test strips to ophthalmic devices.

Study: FDA’s Breakthrough Path Speeds Access, But Raises Safety Questions

 
• By 

Research recently published in JAMA Internal Medicine found that the FDA met its review timeline goals for the majority of breakthrough devices – but also revealed some apparent shortcomings in safety data supporting the submissions.